Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PTGIR | P43119 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416166 | 0.90 | ENPP2 (0.58) | MGLLENPP2NR1H4 | |
| SCHEMBL3416589 | 0.89 | ENPP2 (0.50) | MGLLENPP2NR1H4PPARDCYP3A4 | |
| SCHEMBL3419017 | 0.89 | NR1H4 (0.52) | MGLLENPP2NR1H4 | |
| SCHEMBL3417457 | 0.88 | ENPP2 (0.49) | MGLLENPP2NR1H4TBXA2R | |
| SCHEMBL3416294 | 0.79 | PTGDR2 (0.69) | MGLLENPP2PTGDR2PPARATBXA2R | |
| SCHEMBL4337850 | 0.79 | PPARA (0.59) | PPARAPPARD | |
| SCHEMBL3411988 | 0.79 | ENPP2 (0.42) | MGLLENPP2NR1H4PTGDR2TBXA2R | |
| SCHEMBL13810405 | 0.77 | PPARA (0.55) | PPARAPPARD | |
| SCHEMBL3415287 | 0.76 | PTGDR2 (0.64) | MGLLENPP2PTGDR2PPARATBXA2R | |
| SCHEMBL3415458 | 0.75 | PTPN11 (0.49) | ENPP2NR1H4PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | MGLL 3532/4885ENPP2 833/4885NR1H4 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.